Corton Capital Inc. Invests $223,000 in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Corton Capital Inc. purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 946 shares of the biopharmaceutical company's stock, valued at approximately $223,000.

Several other institutional investors also recently added to or reduced their stakes in the company. Jennison Associates LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $61,160,000. Strategic Financial Concepts LLC purchased a new position in Alnylam Pharmaceuticals in the 4th quarter valued at $41,529,000. Truist Financial Corp increased its stake in Alnylam Pharmaceuticals by 136.6% in the 4th quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company's stock valued at $1,035,000 after buying an additional 2,539 shares during the period. Sumitomo Mitsui Trust Group Inc. increased its stake in Alnylam Pharmaceuticals by 3.0% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company's stock valued at $67,464,000 after buying an additional 8,462 shares during the period. Finally, Assenagon Asset Management S.A. raised its position in Alnylam Pharmaceuticals by 13.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company's stock worth $4,687,000 after buying an additional 2,285 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CFO Jeffrey V. Poulton sold 967 shares of the company's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $246,749.39. Following the completion of the sale, the chief financial officer now directly owns 32,786 shares of the company's stock, valued at approximately $8,366,003.62. This represents a 2.86 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Yvonne Greenstreet sold 1,213 shares of the business's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $309,521.21. Following the completion of the sale, the chief executive officer now owns 81,526 shares in the company, valued at $20,802,989.42. The trade was a 1.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 7,392 shares of company stock worth $1,875,627. 1.50% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ:ALNY traded down $6.35 during trading on Friday, reaching $252.00. 656,363 shares of the company's stock traded hands, compared to its average volume of 903,611. The stock has a market capitalization of $32.86 billion, a P/E ratio of -116.13 and a beta of 0.17. Alnylam Pharmaceuticals, Inc. has a 12 month low of $144.73 and a 12 month high of $304.39. The company has a 50 day moving average of $250.53 and a 200-day moving average of $253.98. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to analyst estimates of $584.32 million. The company's revenue was up 20.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.16) earnings per share. On average, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Bank of America boosted their target price on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. William Blair reiterated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. Needham & Company LLC reaffirmed a "buy" rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 9th. Morgan Stanley lowered their target price on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating on the stock in a report on Friday, April 11th. Finally, Canaccord Genuity Group boosted their price objective on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. One investment analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $319.17.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.